A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis - Concepedia

Concepedia

Publication | Open Access

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

DOI Full Paper Access

75

Citations

18

References

2022

Year

Christopher L. Bowlus, Michael Galambos, Richard Aspinall, Gideon M. Hirschfield, David E.J. Jones, Yvonne Dörffel, Stuart C. Gordon, Stephen A. Harrison, Andreas E. Kremer, Marlyn J. Mayo,

Journal of Hepatology

HepatologyBiliary Tract52-Week StudyGastroenterologyPathologyPrimary Sclerosing CholangitisBiliary DisorderPrimary Biliary CholangitisPrimary Biliary CirrhosisCholangiopathiesMedicinePhase IiAutoimmune Liver Disease

References

	Year	Citations

Page 1

Page 1